

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO SB 08B (10-01)
Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE
to respond to a collection of information unless it contains a valid OMB

Substitute for form 1449B PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/974.703
		Filing Date	10/10/2001
		First Named Inventor	Douglas E. Vaughan
		Group Art Unit	1648 1659
		Examiner Name	PATEN
Sheet	1	of	1
		Attorney Docket Number	1242/39/2

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
PP	12	RIDKER P.M., ET AL., "Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function." Circulation, Vol. 87 (No. 6), p. 1969-1973, (June 17, 1993). (Abstract)	
↑	13	KOH, K. K., ET AL., "Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women." N. England J. of Med., Vol. 336 (No. 10), p. 683-690, (March 6, 1997). (Abstract)	
	14	BROWN, NANCY J., ET AL., "Angiotensin-Converting Enzyme Inhibitors," Cardiovascular Drugs, American Heart Association, Inc., p. 1411-1420, (April 1998).	
	15	THOGERSEN, ANNA M., ET AL., "High Plasminogen Activator Inhibitor and Tissue Plasminogen Activator Levels in Plasma Precede a First Acute Myocardial Infarction in Both Men and Women - Evidence for the Fibrinolytic System as an Independent Primary Risk Factor," Circulation, American Heart Association, Inc., p. 2241-2247, (November 24, 1998).	
	16	BROWN, NANCY J., ET AL., "Effect of Activation and Inhibition of the Renin-Angiotensin System on Plasma PAI-1," Hypertension, American Heart Association, Inc., p. 965-971, (December 1, 1998).	
	17	VAUGHAN, DOUGLAS E., "Plasminogen Activator Inhibitor-1: A Common Denominator in Cardiovascular Disease," J. of Investigative Medicine, Vol. 46 (No.8) p. 370-376 (October 8, 1998).	
	18	MERVAALA, EERO M.A., ET AL., "Monocyte Infiltration and Adhesion Molecules in a Rat Model of High Human Renin Hypertension," Hypertension, p. 389-395 (January, 1999).	
	19	GARDEMANN, ANDREAS ET AL., "The 4G/4G Genotype of the Plasminogen Activator Inhibitor 4G/5G Gene Polymorphism is Associated with Coronary Atherosclerosis in Patients at High Risk for this Disease," Thromb Haemost Vol. 82, p. 1121-1126 (1999).	
	20	GRANCHA, S. ET AL., "Plasminogen Activator Inhibitor-1 (PAI-1) Promoter 4G/5G Genotype and Increased PAI-1 Circulating Levels in Postmenopausal Women with Coronary Artery Disease," Thromb Haemost Vol. 81, P. 516-521 (1999).	
↓	21	BROWN, NANCY J., ET AL. "Comparative Effect of Angiotensin-converting Enzyme Inhibition and Angiotensin II Type 1 Receptor Antagonism on Plasma Fibrinolytic Balance in Humans," Hypertension, p. 285-290 (August 1999).	
PP	22	LOTTERMOSER, K., ET AL. "Effects of captopril on fibrinolytic function in healthy humans," Eur. J. Med. Res., Vol. 4, (No 1) p.31-34 (January 26, 1999).	

Examiner Signature	<i>Patricia A. Ball</i>	Date Considered	11/25/03
--------------------	-------------------------	-----------------	----------

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609 Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Approved for use through 10.31.2002 OMB 0651-0031
U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/974.703
				Filing Date	10/10/2001
				First Named Inventor	Douglas E. Vaughan
				Art Unit	1646 1654
				Examiner Name	PATEN
				Attorney Docket Number	1242/39/2
Sheet	1	of	1		

[illegible]

FOREIGN PATENT DOCUMENTS						Class/Subject	
Examiner Initials*	Cite No. 1	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant; Passages or Relevant Figures Appear	T6
		Country Code 3	-Number ⁴ -K nd Code ⁵ (if known)				
	6	WO	99/20260	04/29/1999	Eurogene Limited		
	7	WO	99/34823	07/15/1999	University of Utah		
	8	WO	00 51642	09/08/2000	G.D. Searle & Co.		
	9	WO	00 69412	11/23/2000	Talaria Therapeuti		
	10	WO	01 15674 A2	03/08/2001	Aventis Pharma		
	11	WO	01 36351 A2	05/25/2001	Corvas Int'l		

Examiner Signature	<i>Kathleen Hill</i>	Date Considered	11/25/03
-----------------------	----------------------	--------------------	----------

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609 Draw line through citation if not in conformance and not considered Include copy of this form with next communication to applicant

1. Applicant's unique citation designation number (optional). ² See Kind's Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the senai number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement. This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO Assistant Commissioner for Patents, Washington, DC 20231**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO SB 08B (10-01)
Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/974,703
		Filing Date	10/10/2001
		First Named Inventor	Douglas E. Vaughan
		Group Art Unit	1646/1654
		Examiner Name	PATEN
Sheet 2	1	of 2	1
		Attorney Docket Number	1242/39/2

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS); title of the article (when appropriate); title of the item (book, magazine, journal, serial, symposium, catalog, etc.); date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
PP	23	ERDEM, Y., ET AL. "Effects of Angiotensin Converting Enzyme and Angiotensin II Receptor Inhibition on Impaired Fibrinolysis in Systemic Hypertension." Am. J. Hypertens. Vol. 12 (11 pt 1) p. 1071-1076 (November, 1999). (Abstract)	
↑	24	YUSUF, S., ET AL. "Summary of Randomized Trials of Angiotensin Converting Enzyme Inhibitors." Clin. Exp. Hypertens. Vol. 12 (Nos 5-6) p. 835-845 (Jul-Aug 1999). (Abstract)	
↓	25	KOHLER, HANS P., ET AL. "Plasminogen-Activator Inhibitor Type 1 and Coronary Artery Disease." The New England J. of Medicine. Vol. 342 (No 24) p. 1792-1801 (June 15, 2000).	
↓	26	SCHALKWIJK, C.G., ET AL. "ACE-inhibition modulates some endothelial functions in healthy subjects and in normotensive type I diabetic patients." European J. of Clinical Investigation, Vol. 30, p. 853-860 (2000).	
PP	27	JNEID, H. ET AL., "Coronary Artery Disease in Women: Different, Often Undertreated," Cleve. Clin. J. Med., Vol. 68 (No 5), P. 441-448 (May 2001).	

Examiner Signature	<i>[Signature]</i>	Date Considered	11/26/03
--------------------	--------------------	-----------------	----------

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO Assistant Commissioner for Patents, Washington, DC 20231.